Epstein-Barr virus (EBV) is the cause of heterophilepositive infectious mononucleosis (IM), which is characterized by fever, sore throat, lymphadenopathy, and atypical lymphocytosis. EBV is also associated with several human tumors, including nasopharyngeal carcinoma, Burkitt’s lymphoma, Hodgkin’s disease, and (in patients with immunodeficiencies) B-cell lymphoma. The virus, a member of the family Herpesviridae, consists of a linear DNA core surrounded by a nucleocapsid and an envelope that contains glycoproteins. The two types of EBV that are widely prevalent in nature are not distinguishable by conventional serologic tests.
EBV infections occur worldwide.These infections are most common in early childhood, with a second peak during late adolescence. By adulthood, more than 90% of individuals have been infected and have antibodies to the virus. IM is usually a disease of young adults. In lower socioeconomic groups and in areas of the world with lower standards of hygiene (e.g., developing countries), EBV tends to infect children at an early age, and symptomatic IM is uncommon. In areas with higher standards of hygiene, infection with EBV is often delayed until adulthood, and IM is more prevalent. EBV is spread by contact with oral secretions.The virus is frequently transmitted from asymptomatic adults to infants and among young adults by transfer of saliva during kissing.Transmission by less intimate contact is rare. EBV has been transmitted by blood transfusion and by bone marrow transplantation. More than 90% of asymptomatic seropositive individuals shed the virus in oropharyngeal secretions. Shedding is increased in immunocompromised patients and those with IM.
EBV is transmitted by salivary secretions.The virus infects the epithelium of the oropharynx and the salivary glands and is shed from these cells.Although B cells may become infected after contact with epithelial cells, studies suggest that lymphocytes in the tonsillar crypts can be infected directly. The virus then spreads through the bloodstream. The proliferation and expansion of EBV-infected B cells along with reactive T cells during IM result in enlargement of lymphoid tissue. Polyclonal activation of B cells leads to the production of antibodies to host-cell and viral proteins. During the acute phase of IM, up to 1 in every 100 B cells in the peripheral blood is infected by EBV; after recovery, 1–50 in every 1 million B cells is infected. During IM, there is an inverted CD4+/CD8+T-cell ratio. The percentage of CD4+ T cells decreases, whereas there are large clonal expansions of CD8+ T cells; up to 40% of CD8+ T cells are directed against EBV antigens during acute infection.
Data suggest that memory B cells, not epithelial cells, are the reservoir for EBV in the body. When patients are treated with acyclovir, shedding of EBV from the oropharynx stops, but the virus persists in B cells. The EBV receptor (CD21) on the surface of B cells is also the receptor for the C3d component of complement. EBV infection of epithelial cells results in viral replication and production of virions. When B cells are infected by EBV in vitro, they become transformed and can proliferate indefinitely. During latent infection of B cells, only the EBV nuclear antigens (EBNAs), latent membrane proteins (LMPs), and small EBV RNAs are expressed in vitro. EBV-transformed B cells secrete immunoglobulin; only a small fraction of cells produce virus. Cellular immunity is more important than humoral immunity in controlling EBV infection. In the initial phase of infection, suppressor T cells, natural killer cells, and nonspecific cytotoxic T cells are important in controlling the proliferation of EBV-infected B cells. Levels of markers of T-cell activation and serum interferon (IFN) ã are elevated. Later in infection, HLA-restricted cytotoxic T cells that recognize EBNAs and LMPs and destroy EBVinfected cells are generated. Studies have shown that one of the late genes expressed during EBV replication, BCRF1, is a homologue of interleukin 10 and can inhibit the production of IFN-ã by mononuclear cells in vitro. If T-cell immunity is compromised, EBV-infected B cells may begin to proliferate. When EBV is associated with lymphoma, virus-induced proliferation is but one step in a multistep process of neoplastic transformation. In many EBV-containing tumors, LMP-1 mimics members of the tumor necrosis factor receptor family (e.g., CD40), transmitting growth-proliferating signals.
Signs and Symptoms Most EBV infections in infants and young children either are asymptomatic or present as mild pharyngitis with or without tonsillitis. In contrast, up to 75% of infections in adolescents present as IM. IM in the elderly presents relatively often as nonspecific symptoms, including prolonged fever, fatigue,myalgia, and malaise. In contrast, pharyngitis, lymphadenopathy, splenomegaly, and atypical lymphocytes are relatively rare in elderly patients. The incubation period for IM in young adults is ∼4–6 weeks. A prodrome of fatigue, malaise, and myalgia may last for 1–2 weeks before the onset of fever, sore throat, and lymphadenopathy. Fever is usually low-grade and is most common in the first 2 weeks of the illness; however, it may persist for >1 month. Common signs and symptoms are listed along with their frequencies in Table 82-1. Lymphadenopathy and pharyngitis are most prominent during the first 2 weeks of the illness, whereas splenomegaly is more prominent during the second and third weeks. Lymphadenopathy most often affects the posterior cervical nodes but may be generalized. Enlarged lymph nodes are frequently tender and symmetric but are not fixed in place. Pharyngitis, often the most prominent sign, can be accompanied by enlargement of the tonsils with an exudate resembling that of streptococcal pharyngitis.
A morbilliform or papular rash, usually on the arms or trunk, develops in ∼5% of cases (Fig. 82-1). Most patients treated with ampicillin develop a macular rash; this rash is not predictive of future adverse reactions to penicillins. Erythema nodosum and erythema multiforme have also been described. Most patients have symptoms for 2–4 weeks, but malaise and difficulty concentrating can persist for months. Laboratory Findings The white blood cell count is usually elevated and peaks at 10,000–20,000/ìL during the second or third week of illness. Lymphocytosis is usually demonstrable, with >10% atypical lymphocytes. The latter cells are enlarged lymphocytes that have abundant cytoplasm, vacuoles, and indentations of the cell membrane (Fig. 82-2).CD8+ cells predominate among the atypical lymphocytes. Low-grade neutropenia and thrombocytopenia are common during the first month of illness. Liver function is abnormal in >90% of cases. Serum levels of aminotransferases and alkaline phosphatase are usually mildly elevated.The serum concentration of bilirubin is elevated in ∼40% of cases. Complications Most cases of IM are self-limited. Deaths are very rare and most often are due to central nervous system (CNS) complications, splenic rupture, upper airway obstruction, or bacterial superinfection.
When CNS complications develop, they usually do so during the first 2 weeks of EBV infection; in some patients, especially children, they are the only clinical manifestations of IM. Heterophile antibodies and atypical lymphocytes may be absent. Meningitis and encephalitis are the most common neurologic abnormalities, and patients may present with headache, meningismus, or cerebellar ataxia. Acute hemiplegia and psychosis have also been described. The cerebrospinal fluid (CSF) contains mainly lymphocytes, with occasional atypical lymphocytes. Most cases resolve without neurologic sequelae.Acute EBV infection has also been associated with cranial nerve palsies (especially those involving cranial nerve VII), Guillain- Barré syndrome, acute transverse myelitis, and peripheral neuritis. Autoimmune hemolytic anemia occurs in ∼2% of cases during the first 2 weeks. In most cases, the anemia is Coombs-positive, with cold agglutinins directed against the i red blood cell antigen. Most patients with hemolysis have mild anemia that lasts for 1–2 months, but some patients have severe disease with hemoglobinuria and jaundice.
Nonspecific antibody responses may also include rheumatoid factor, antinuclear antibodies, anti–smooth muscle antibodies, antiplatelet antibodies, and cryoglobulins. IM has been associated with red-cell aplasia, severe granulocytopenia, thrombocytopenia, pancytopenia, and hemophagocytic syndrome. The spleen ruptures in <0.5% of cases. Splenic rupture is more common among male than female patients and may manifest as abdominal pain, referred shoulder pain, or hemodynamic compromise. Hypertrophy of lymphoid tissue in the tonsils or adenoids can result in upper airway obstruction, as can inflammation and edema of the epiglottis, pharynx, or uvula. About 10% of patients with IM develop streptococcal pharyngitis after their initial sore throat resolves. Other rare complications associated with acute EBV infection include hepatitis (which can be fulminant), myocarditis or pericarditis with electrocardiographic changes, pneumonia with pleural effusion, interstitial nephritis, genital ulcerations, and vasculitis. EBV-Associated Diseases Other Than IM EBV-associated lymphoproliferative disease has been described in patients with congenital or acquired immunodeficiency, including those with severe combined immunodeficiency, patients with AIDS, and recipients of bone marrow or organ transplants who are receiving immunosuppressive drugs (especially cyclosporine).
Proliferating EBV-infected B cells infiltrate lymph nodes and multiple organs, and patients present with fever and lymphadenopathy or gastrointestinal symptoms. Pathologic studies show B-cell hyperplasia or poly- or monoclonal lymphoma. The X-linked lymphoproliferative syndrome (Duncan’s disease) is a recessive disorder of young boys who have a normal response to childhood infections but develop fatal lymphoproliferative disorders after infection with EBV. The protein associated with this syndrome (SAP) binds to a protein that mediates interactions of B and T cells. Most patients with this syndrome die of acute IM. Others develop hypogammaglobulinemia, malignant B-cell lymphomas, aplastic anemia, or agranulocytosis. IM has also proved fatal to some patients with no obvious preexisting immune abnormality. Oral hairy leukoplakia (Fig. 82-3) is an early manifestation of infection with HIV in adults (Chap. 90). Most patients present with raised, white corrugated lesions on the tongue (and occasionally on the buccal mucosa) that contain EBV DNA. Children infected with HIV can develop lymphoid interstitial pneumonitis; EBV DNA is often found in lung tissue from these patients. Patients with chronic fatigue syndrome may have titers of antibody to EBV that are elevated but are not significantly different from those in healthy EBV-seropositive adults. Although some patients have malaise and fatigue that persist for weeks or months after IM, persistent EBV infection is not a cause of chronic fatigue syndrome. Chronic active EBV infection is very rare and is distinct from chronic fatigue syndrome.The affected patients have an illness lasting >6 months, with elevated levels of EBV DNA in the blood, very high titers of antibody to EBV, and evidence of organ involvement, including hepatosplenomegaly, lymphadenopathy, and pneumonitis, uveitis, or neurologic disease. EBV is associated with several malignancies. About 15% of cases of Burkitt’s lymphoma in the United States and ∼90% of those in Africa are associated with EBV.
African patients with Burkitt’s lymphoma have high levels of antibody to EBV, and their tumor tissue usually contains viral DNA. Malaria infection in Africa may impair cellular immunity to EBV and induce polyclonal B cell activation with an expansion of EBV-infected B cells. These changes may enhance the proliferation of B cells, increasing the likelihood of a c-myc translocation—the hallmark of Burkitt’s lymphoma. EBV-containing Burkitt’s lymphoma also occurs in patients with AIDS. Anaplastic nasopharyngeal carcinoma is uniformly associated with EBV; the affected tissues contain viral DNA and antigens. Patients with nasopharyngeal carcinoma often have elevated titers of antibody to EBV. High levels of EBV plasma DNA before treatment or detectable levels of EBV DNA after radiation therapy correlate with lower rates of overall survival and relapse-free survival among patients with nasopharyngeal carcinoma. EBV has been associated with Hodgkin’s disease, especially the mixed-cellularity type. Patients with Hodgkin’s disease often have elevated titers of antibody to EBV. In about half of cases, viral DNA and antigens are found in Reed-Sternberg cells.The risk of EBV-positive Hodgkin’s disease is significantly increased in young adults after EBVseropositive IM.About 50% of non-Hodgkin’s lymphomas in patients with AIDS are EBV-positive. In some cases, EBV DNA has been detected in tumors from immunocompetent patients with tonsillar carcinoma, angioimmunoblastic lymphadenopathy, angiocentric nasal NK/T-cell immunoproliferative lesions,T-cell lymphoma, thymoma, gastric carcinoma, and CNS lymphoma.
Studies have demonstrated viral DNA in leiomyosarcomas from AIDS patients and in smooth-muscle tumors from organ transplant recipients. Virtually all CNS lymphomas in AIDS patients are associated with EBV. Although serologic studies have found higher levels of antibodies to EBV before the onset of multiple sclerosis in persons ≥25 years old, other studies (including measurement of EBV antibody titers in the CSF) are needed to ascertain a possible causal relationship.
Serologic Testing The heterophile test is used for the diagnosis of IM in children and adults (Table 82-2). In the test for this antibody, human serum is absorbed with guinea pig kidney, and the heterophile titer is defined as the greatest serum dilution that agglutinates sheep, horse, or cow erythrocytes. Although heterophile antibody binds to certain animal erythrocytes, it does not interact with EBV proteins. A titer of ≥40-fold is diagnostic of acute EBV infection in a patient who has symptoms compatible with IM and atypical lymphocytes.Tests for heterophile antibodies are positive in 40% of patients with IM during the first week of illness and in 80–90% during the third week.Therefore, repeated testing may be necessary, especially if the initial test is performed early. Tests usually remain positive for 3 months after the onset of illness, but heterophile antibodies can persist for up to 1 year. These antibodies usually are not detectable in children <5 years of age, in the elderly, or in patients presenting with symptoms not typical of IM. The commercially available monospot test for heterophile antibodies is somewhat more sensitive than the classic heterophile test.The monospot test is ∼75% sensitive and ∼90% specific compared with EBVspecific serologies. False-positive monospot results are more common among persons with connective tissue disease, lymphoma,viral hepatitis,and malaria. EBV-specific antibody testing is used for patients with suspected acute EBV infection who lack heterophile antibodies and for patients with atypical infections (Table 82-2). Titers of IgM and IgG antibodies to viral capsid antigen (VCA) are elevated in the serum of more than 90% of patients at the onset of disease.
IgM antibody to VCA is most useful for the diagnosis of acute IM because it is present at elevated titers only during the first 2–3 months of the disease; in contrast, IgG antibody to VCA is usually not useful for diagnosis of IM but is often used to assess past exposure to EBV because it persists for life. Seroconversion to EBNA positivity is also useful for the diagnosis of acute infection with EBV. Antibodies to EBNA become detectable relatively late (3–6 weeks after the onset of symptoms) in nearly all cases of acute EBV infection and persist for the lifetime of the patient. These antibodies may be lacking in immunodeficient patients and in those with chronic active EBV infection. Titers of other antibodies may also be elevated in IM; however, these elevations are less useful for diagnosis. Antibodies to early antigens (EAs) are found either in a diffuse pattern in the nucleus and cytoplasm of infected cells (EA-D antibody) or restricted to the cytoplasm (EA-R antibody). These antibodies are detectable 3–4 weeks after the onset of symptoms in patients with IM. About 70% of individuals with IM have EA-D antibodies during the illness; the presence of EA-D antibodies is especially likely in patients with relatively severe disease. These antibodies usually persist for only 3–6 months. Levels of EA-D antibodies are also elevated in patients with nasopharyngeal carcinoma or chronic active EBV infection. EA-R antibodies are only occasionally detected in patients with IM but are often found at elevated titers in patients with African Burkitt’s lymphoma or chronic active EBV infection. IgA antibodies to EBV antigens have proved useful for the identification of patients with nasopharyngeal carcinoma and of persons at high risk for the disease. Other Studies Detection of EBV DNA, RNA, or proteins has been valuable in demonstrating the association of the virus with various malignancies.
The polymerase chain reaction has been used to detect EBV DNA in the CSF of some AIDS patients with lymphomas and to monitor the amount of EBV DNA in the blood of patients with lymphoproliferative disease. Detection of high levels of EBV DNA in blood during the first few weeks of IM may be useful if serologic studies yield equivocal results. Culture of EBV from throat washings or blood is not helpful in the diagnosis of acute infection, since EBV commonly persists in the oropharynx and in B cells for the lifetime of the infected individual. Differential Diagnosis Whereas ∼90% of cases of IM are due to EBV, 5–10% of cases are due to cytomegalovirus (CMV).CMV is the most common cause of heterophile-negative mononucleosis, usually presenting in older patients. IM caused by CMV is associated with a lower frequency of sore throat, splenomegaly, and lymphadenopathy than IM due to EBV. Less common causes of IM include acute infection with Toxoplasma, HIV, human herpesvirus 6, and hepatitis viruses as well as drug hypersensitivity reactions. Other diseases that share some of the features of IM include rubella, acute infectious lymphocytosis in children, and lymphoma or leukemia.
Therapy for IM consists of supportive measures, with rest and analgesia. Excessive physical activity during the first month should be avoided to reduce the possibility of splenic rupture, which necessitates splenectomy. Glucocorticoid therapy is not indicated for uncomplicated IM and in fact may predispose to bacterial superinfection. Prednisone (40–60 mg/d for 2–3 days, with subsequent tapering of the dose over 1–2 weeks) has been used for the prevention of airway obstruction in patients with severe tonsillar hypertrophy, for autoimmune hemolytic anemia, and for severe thrombocytopenia. Glucocorticoids have also been administered to a few selected patients with severe malaise and fever and to patients with severe CNS or cardiac disease. Acyclovir has had no significant clinical impact on IM in controlled trials. In one study, the combination of acyclovir and prednisolone had no significant effect on the duration of symptoms of IM. Acyclovir, at a dosage of 400–800 mg five times daily, has been effective for the treatment of oral hairy leukoplakia (despite common relapses). The posttransplantation EBV lymphoproliferative syndrome (Chap. 12) generally does not respond to antiviral therapy. When possible, therapy should be directed toward reduction of immunosuppression (Table 82-3). IFN-á or antibody to CD20 has been effective in some cases. Infusions of donor lymphocytes are often effective for stem-cell transplant recipients, although graft-versus-host disease can occur. Infusions of EBV-specific cytotoxic T cells have been used to prevent EBV lymphoproliferative disease in high-risk settings, as well as to treat the disease. Infusion of autologous EBV-specific cytotoxic T lymphocytes has shown promise in small studies of patients with nasopharyngeal carcinoma and Hodgkin’s disease. Treatment of two cases of X-linked lymphoproliferative syndrome with antibody to CD20 resulted in a successful outcome of what otherwise would probably have been fatal acute EBV infection.